These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 12186473)

  • 1. Failure of B7.1-modified tumor to evoke full activation of CD8+ tumor-infiltrating lymphocytes in the central nervous system: prevention of parental tumor growth in the subcutaneous environment.
    Ando H; Saio M; Tamakawa N; Ohe N; Nakayama T; Yu H; Kaku Y; Iwama T; Shinoda J; Sakai N; Takami T
    J Neurosurg; 2002 Aug; 97(2):432-40. PubMed ID: 12186473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7.1 immunogene therapy effectively activates CD(4+) tumor-infiltrating lymphocytes in the central nervous system in comparison with B7.2 gene therapy.
    Ando H; Saio M; Ohe N; Tamakawa N; Yu H; Nakayama T; Yoshimura S; Kaku Y; Iwama T; Shinoda J; Sakai N; Takami T
    Int J Oncol; 2002 Apr; 20(4):807-12. PubMed ID: 11894129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 activated microglia engulf tumor infiltrating T cells in the central nervous system.
    Tamakawa N; Saio M; Suwa T; Ohe N; Yoshimura S; Iwama T; Shinoda J; Sakai N; Takami T
    Int J Mol Med; 2004 Apr; 13(4):497-503. PubMed ID: 15010848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines.
    Cayeux S; Beck C; Aicher A; Dörken B; Blankenstein T
    Eur J Immunol; 1995 Aug; 25(8):2325-31. PubMed ID: 7545119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas.
    Wang X; Wang T; Xu M; Xiao L; Luo Y; Huang W; Zhang Y; Geng W
    Hum Immunol; 2014 Dec; 75(12):1203-9. PubMed ID: 25446402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mechanism for selective recruitment of CD8 T cells into B7-1-transfected plasmacytoma: role of macrophage-inflammatory protein 1alpha.
    Maric M; Chen L; Sherry B; Liu Y
    J Immunol; 1997 Jul; 159(1):360-8. PubMed ID: 9200474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-H4 reduces the infiltration of CD8+T cells and induces their anti-tumor dysfunction in gliomas.
    Qi Y; Hu L; Ji C; Yang X; Yao J; Chen D; Yao Y
    Neoplasia; 2024 Aug; 54():101007. PubMed ID: 38796932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
    Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
    Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
    Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
    J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.
    Fields PE; Finch RJ; Gray GS; Zollner R; Thomas JL; Sturmhoefel K; Lee K; Wolf S; Gajewski TF; Fitch FW
    J Immunol; 1998 Nov; 161(10):5268-75. PubMed ID: 9820499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
    Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
    Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: implications for the lesion pathogenesis of multiple sclerosis.
    Ortler S; Leder C; Mittelbronn M; Zozulya AL; Knolle PA; Chen L; Kroner A; Wiendl H
    Eur J Immunol; 2008 Jun; 38(6):1734-44. PubMed ID: 18421793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
    Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site-specific immune response to implanted gliomas.
    Proescholdt MA; Merrill MJ; Ikejiri B; Walbridge S; Akbasak A; Jacobson S; Oldfield EH
    J Neurosurg; 2001 Dec; 95(6):1012-9. PubMed ID: 11765816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
    Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
    Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
    Velicu S; Han Y; Ulasov I; Brown IE; El Andaloussi A; Gajewski TF; Lesniak MS
    J Neuroimmunol; 2006 May; 174(1-2):74-81. PubMed ID: 16504307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.